Celsion Corporation Announces Formation of Vaccine Advisory Board
12 févr. 2021 08h30 HE
|
Celsion CORP
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) --...
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
22 janv. 2021 08h40 HE
|
Celsion CORP
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
16 nov. 2020 08h30 HE
|
Celsion CORP
Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00...
Celsion Corporation Issues Letter to Stockholders
12 oct. 2020 08h00 HE
|
Celsion CORP
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
14 juil. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
13 juil. 2020 08h30 HE
|
Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
22 juin 2020 15h00 HE
|
Celsion CORP
Lawrenceville, NJ, June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to...
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
15 mai 2020 08h00 HE
|
Celsion CORP
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion CEO Issues Letter to Stockholders
03 mars 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...
Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
04 nov. 2019 08h00 HE
|
Celsion CORP
The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is...